Chimeric antigen receptor (CAR) T-cell therapy is increasingly used in both oncologic and nononcologic conditions. Although low-grade neurotoxicity may be easily treated, severe neurotoxicity remains clinically challenging and many times fatal. We present the case of a young adult with relapsed acute lymphoblastic leukemia who developed grade 4 immune effector cell–associated neurotoxicity syndrome (ICANS), manifesting as severe cerebral edema refractory to first-line therapies. We share our treatment strategy consisting of multiple lines of targeted immunotherapy and proactive intracranial pressure monitoring. The patient survived and continues to remain in remission with meaningful neurologic recovery. Because of the growing use of chimeric antigen receptor T-cell therapies, neurologists need to be aware and ready to treat these potentially fatal cases.
CohenADParekhSSantomassoBD, et al.Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32. doi: https://doi.org/10.1038/s41408-022-00629-1.
2.
HayKAHanafiLALiD, et al.Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood. 2017;130(21):2295-2306.
3.
KarschniaPJordanJTForstDA, et al.Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212-2221. doi: https://doi.org/10.1182/blood-2018-12-893396. Epub 2019 Feb 26.
4.
PasquiniMCHuZHCurranK, et al.Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424. doi: https://doi.org/10.1182/bloodadvances.2020003092. Erratum in: Blood Adv. 2021 Feb 23;5(4):1136. Erratum in: Blood Adv. 2022 Mar 22;6(6):1731.
5.
ZhangHYanZWangY, et al.Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma. Front Immunol. 2022;13:965224. doi: https://doi.org/10.3389/fimmu.2022.965224.
6.
PensatoUMuccioliLZinzaniP, et al.Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review. J Neurol. 2022;269(8):4560-4563. doi: https://doi.org/10.1007/s00415-022-11117-8. Epub 2022 Apr 8. Erratum in: J Neurol. 2022 Jun 8.
7.
SantomassoBDNastoupilLJAdkinsS, et al.Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. JCO. 2021;39(35):3978-3992.
8.
SilvermanLBBlonquistTMHuntSK, et al.Randomized study of pegasparagase (SS-PEG) and calaspargase pegol (SC-PEG) in pediatric patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma: results of DFCI ALL Consortium Protocol 11-001. Blood. 2016;128(22):175-175.
9.
GardnerRACeppiFRiversJ, et al.Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134(24):2149-2158.
10.
StratiPAhmedSKebriaeiP, et al.Management of grade 4 immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy. J Immunother Cancer. 2020;8(2):e001559. doi:https://doi.org/10.1136/jitc-2020-001559.
11.
Navarro-MillánISattuiSELakhanpalAZisaDSiegelCHCrowMK. Use of anakinra to prevent mechanical ventilation in severe COVID-19: a case series. Arthritis Rheumatol. 2020;72(12):1990-1997. doi:https://doi.org/10.1002/art.41422.
12.
WehrliMGallagherKChenYB, et al.Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer. 2022;10(1):e003847. doi: https://doi.org/10.1136/jitc-2021-003847.
13.
GazeauNLiangECWuQV, et al.Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023;29(7):430-437. doi:https://doi.org/10.1016/j.jtct.2023.04.001.
14.
ParkJHNathKDevlinSM, et al.CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med. 2023;29(7):1710-1717. doi:https://doi.org/10.1038/s41591-023-02404-6.
15.
StratiPAhmedSKebriaeiP, et al.Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020;4(13):3123-3127. doi: https://doi.org/10.1182/bloodadvances.2020002328.
16.
LipeBCRenaudT. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting. J Oncol Pharm Pract. 2023;29(4):1006-1010. doi: https://doi.org/10.1177/10781552221140320.
17.
LeRQLiLYuanW, et al.FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943-947. doi: https://doi.org/10.1634/theoncologist.2018-0028.
18.
MunshiNCAnderson LDJrShahN, et al.Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-716.
